David Pot

Dr. David Pot

orcid

Research Focus & Metrics

Representative Publications

View All Publications
1 October 2013 in Cell
Verified
Journal Article
Closed access
CBCameron W. Brennan
Cameron W. Brennan
RVRoel G.W. Verhaak
Roel G.W. Verhaak
AMAaron McKenna
Aaron McKenna
BCBenito Campos
Benito Campos
HNHoutan Noushmehr
Houtan Noushmehr
RMRoger McLendon
Roger McLendon

1 January 1997 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
AKAnke Klippel
Anke Klippel
WKW. Michael Kavanaugh
W. Michael Kavanaugh
DPDavid Pot
David Pot
LWLewis T. Williams
Lewis T. Williams
Phosphatidylinositol (PI) 3-kinase is a cytoplasmic signaling molecule that is recruited to activated growth factor receptors after growth factor stimulation of cells. Activation of PI 3-kinase results in increased intracellular levels of 3' phosphorylated inositol phospholipids and the induction of signaling responses, including the activation of the protein kinase Akt, which is also known as RAC-PK or PKB. We tested the possibility that the phospholipid products of PI 3-kinase directly mediate the activation of Akt. We have previously described a constitutively active PI 3-kinase, p110, which can stimulate Akt activity. We used purified p110 protein to generate a series of 3' phosphorylated inositol phospholipids and tested whether any of these lipids could activate Akt in vitro. Phospholipid vesicles containing PI3,4 bisphosphate (P2) specifically activated Akt in vitro. By contrast, the presence of phospholipid vesicles containing PI3P or PI3,4,5P3 failed to increase the kinase activity of Akt. Akt could also be activated by synthetic dipalmitoylated PI3,4P2 or after enzymatic conversion of PI3,4,5P3 into PI3,4P2 with the signaling inositol polyphosphate 5' phosphatase SIP. We show that PI3,4P2-mediated activation is dependent on a functional pleckstrin homology domain in Akt, since a point mutation in the pleckstrin homology domain abrogated the response to PI3,4P2. Our findings show that a phospholipid product of PI 3-kinase can directly stimulate an enzyme known to be an important mediator of PI 3-kinase signaling.

1 April 1996 in Current Biology
Verified
Journal Article
Closed access
WKW.M. Kavanaugh
W.M. Kavanaugh
DPDavid Pot
David Pot
SCS.M. Chin
S.M. Chin
MDM. Deuter-Reinhard
M. Deuter-Reinhard
AJA.B. Jefferson
A.B. Jefferson
LWLewis T. Williams
Lewis T. Williams

1 July 1992 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
DPDavid Pot
David Pot
JDJack E. Dixon
Jack E. Dixon

20 January 1999 in Biological Chemistry
Verified
Journal Article
Closed access
PDF file
CTCatherine Tribouley
Catherine Tribouley
MWMarco Wallroth
Marco Wallroth
VCVivien Chan
Vivien Chan
XPXavier Paliard
Xavier Paliard
EFEric Fang
Eric Fang
LWLewis T. Williams
Lewis T. Williams
The TNF family is involved in the regulation of the immune system, and its members have been implicated in a variety of biological events such as apoptosis, cell proliferation, differentiation and survival. Here we present a new member of the TNF family, tumor necrosis factor super family member 20 (TNFSF20) that we have identified from the expressed sequence tag (EST) database and characterized. The human protein is a 285 amino acid long type II transmembrane protein and is 19% homologous to TNF in its extra-cellular domain. TNFSF20 is expressed at the surface of antigen presenting cells such as cells of the macrophagemonocyte lineage and dendritic cells. After treatment with bacterial lipopolysaccharide (LPS), TNFSF20 expression is downregulated at the surface of the expresssing cells, suggesting that the membrane-bound protein gets cleaved, and that a soluble factor is released in the extra-cellular compartment. The soluble form of the recombinant TNFSF20 induces proliferation of resting peripheral blood monocytes (PBMC) and cell death of activated lymphocytes. TNFSF20 might therefore play a critical role in the regulation of cell-mediated immune responses.

31 October 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SRSheila M. Reynolds
Sheila M. Reynolds
MMMichael Miller
Michael Miller
PLPhyliss Lee
Phyliss Lee
KLKalle Leinonen
Kalle Leinonen
SPSuzanne M. Paquette
Suzanne M. Paquette
Ilya ShmulevichIlya Shmulevich
Ilya Shmulevich
The ISB Cancer Genomics Cloud (ISB-CGC) is one of three pilot projects funded by the National Cancer Institute to explore new approaches to computing on large cancer datasets in a cloud environment. With a focus on Data as a Service, the ISB-CGC offers multiple avenues for accessing and analyzing The Cancer Genome Atlas, TARGET, and other important references such as GENCODE and COSMIC using the Google Cloud Platform. The open approach allows researchers to choose approaches best suited to the task at hand: from analyzing terabytes of data using complex workflows to developing new analysis methods in common languages such as Python, R, and SQL; to using an interactive web application to create synthetic patient cohorts and to explore the wealth of available genomic data. Links to resources and documentation can be found at www.isb-cgc.org. Cancer Res; 77(21); e7–10. ©2017 AACR.